Valbenazine Tosylate Market

Valbenazine Tosylate API market is projected to grow at a CAGR of 6.5% between 2025 and 2035. The market growth is driven by rising prevalence of neurological and movement disorders, particularly tardive dyskinesia. Valbenazine, marketed under the brand name Ingrezza®, is the first FDA-approved treatment for tardive dyskinesia, creating strong demand for its active pharmaceutical ingredient (API).

By segment, the pharmaceutical-grade valbenazine tosylate dominates the market, accounting for the largest share in 2024. This is attributed to strict regulatory requirements and the need for high-purity APIs in commercial drug manufacturing. Within applications, tardive dyskinesia treatment remains the leading segment, with emerging research investigating the use of Valbenazine for other hyperkinetic disorders, including Tourette syndrome and Huntington’s disease chorea.

Geographically, the US is the key market for Valbenazine Tosylate API, supported by early FDA approval, reimbursement policies, and a high number of diagnosed patients with tardive dyskinesia. North America accounted for over 60% of the global market share in 2024. However, Asia-Pacific, particularly India and China, is anticipated to register the fastest CAGR due to the rise in local API manufacturing capabilities and increasing focus on neurological disorders.

Prominent players in the market include Neurocrine Biosciences (the original innovator), Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and Dr. Reddy’s Laboratories. Contract manufacturers and specialized API providers, such as Sai Life Sciences and Laurus Labs, are also strengthening their presence by offering high-purity, GMP-compliant Valbenazine Tosylate for global distribution. Strategic partnerships, licensing deals, and capacity expansions are likely to characterize the market landscape in the coming years.